Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17400969 | 0.86 | NQO1 (0.61) | TDP1NQO1TSHRNPC1 | |
| SCHEMBL16519363 | 0.84 | NQO1 (0.46) | CYP1A2CYP2D6CYP2C19TDP1NQO1 | |
| SCHEMBL1951190 | 0.82 | CYP2C9 (0.50) | CYP2C19NQO1MEN1KMT2ATSHR | |
| SCHEMBL5779539 | 0.82 | USP2 (0.45) | CYP1A2CYP2D6CYP2C19L3MBTL1NQO1 | |
| SCHEMBL2329778 | 0.81 | KDM4E (0.46) | TDP1L3MBTL1NQO1MEN1KMT2A | |
| SCHEMBL20539545 | 0.81 | APP (0.44) | TDP1NQO1TSHRAPP | |
| SCHEMBL17400983 | 0.81 | NQO1 (0.43) | TDP1L3MBTL1NQO1MEN1KMT2A | |
| SCHEMBL2334467 | 0.81 | SCN4A (0.46) | CYP1A2NQO1MAOB | |
| SCHEMBL3776385 | 0.81 | LTA4H (0.48) | CYP1A2CYP2D6CYP2C19NQO1TSHR | |
| SCHEMBL6828016 | 0.80 | PPARD (0.50) | L3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681207-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8916561-B2 | Substituted quinoxaline compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916561-B2 | Substituted quinoxaline compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2681207-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | Bioenergenix (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2013-02-21 | — | — | US | disclosed |
| EP-2533636-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | Mapi Pharma Limited (IL) | 2012-12-19 | — | — | EP | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| US-4102888-A | VASODILATORS, ANTITHROMBITIC | MERCK & CO., INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4085125-A | 9-Thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4066675-A | PSORIASIS, THROMBOSIS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4061643-A | ANTIFERTILITY | MERCK & CO., INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4059587-A | 8-AZA-9-OXO-11-THIA-PROSTANOIC ACID DERIVATIVES; VASODILATORS, ANTICLOTTING, REGULATORS OF IMMUNE RESPONSE | MERCK & CO., INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-4055596-A | PHARMACEUTICALS | MERCK & CO., INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4022794-A | VASODILATION | MERCK & CO., INC. (US) | 1977-05-10 | — | — | US | disclosed |
| US-4020177-A | CONTRACEPTIVES | MERCK & CO., INC. (US) | 1977-04-26 | — | — | US | disclosed |
| US-4018802-A | SKIN DISEASES, GROWTH HORMONE STIMULANTS, THROMBUS PREVENTION, IMMUNOLOGY | MERCK & CO., INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-3991106-A | FOR ESTRUS SYNCHRONIZATION AND TREATMENT OF INFERTILITY | MERCK & CO., INC. (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | CYP2F1, CYP4F3, CYP2D6 | CYP1A2 14/4885CYP2D6 3/4885CYP2C19 15/4885 |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | CYP1A2 4287/4885CYP2D6 4460/4885CYP2C19 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.